Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ME - 23andMe Holding Co.
Market Cap 797.97M P/E - EPS this Y -59.40% Ern Qtrly Grth -
Income -521.97M Forward P/E -2.70 EPS next Y 44.50% 50D Avg Chg -7.00%
Sales 247.99M PEG - EPS past 5Y - 200D Avg Chg -26.00%
Dividend N/A Price/Book 1.12 EPS next 5Y - 52W High Chg -73.00%
Recommedations 2.50 Quick Ratio 1.85 Shares Outstanding 315.44M 52W Low Chg 10.00%
Insider Own 3.94% ROA -26.17% Shares Float 312.08M Beta 1.28
Inst Own 43.11% ROE -92.53% Shares Shorted/Prior 32.88M/32.68M Price 1.73
Gross Margin 45.30% Profit Margin -210.48% Avg. Volume 2,436,843 Target Price 1.43
Oper. Margin -180.82% Earnings Date May 26 Volume 2,473,049 Change -4.95%
Healthcare | Diagnostics & Research | United States
About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

23andMe Holding Co. News
04/05/24 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/24/24 Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
03/20/24 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
03/19/24 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago
03/06/24 23andMe Launches New Genetic Reports on Common Forms of Cancer
03/05/24 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
02/23/24 20 Most Valuable Digital Health Companies In The US
02/13/24 Is 23andMe Stock a Smart Buy Right Now?
02/09/24 23andMe Holding Third Quarter 2024 Earnings: US$0.58 loss per share (vs US$0.20 loss in 3Q 2023)
02/08/24 23andMe Stock Slides After DNA-Testing Company's Disappointing Results
02/08/24 23andMe Holding Co. (NASDAQ:ME) Q3 2024 Earnings Call Transcript
02/08/24 Q3 2024 23andMe Holding Co. Earnings Call
02/07/24 How 23AndMe Went From a $6 Billion Valuation to a Penny Stock
02/07/24 23andMe Mulls Possible Split, Shares Fall After Disappointing Results
02/07/24 23andMe Holding Co (ME) Faces Revenue Decline and Net Loss in Q3 FY24
02/07/24 23andMe Reports Third Quarter Fiscal 2024 Financial Results
02/05/24 SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
02/05/24 Main Street is still investing like it’s 2023
02/02/24 23andMe is low on cash and its stock is worth pennies. The CEO wants another chance
01/31/24 23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
ME Chatroom

User Image AnaChart Posted - 7 minutes ago

$ME https://anachart.com/wp-content/uploads/ana_temp/1713279751_soc-img.jpg

User Image diamondjake78 Posted - 24 minutes ago

$ME Welp, new low. Amazing job team. Well done. Incredible products. Amazing pipeline. Brilliant ideas. Any more empty words I can barf onto the promo page?

User Image CogburnBias Posted - 50 minutes ago

$ME Anne must have no friends at this point. When she was with Sergey her previous circles of cronies spend the entire companies marketcap on vacations. She can't convince anyone to invest in her dumpster fire? 5 billion to 190 million in 3 years is impressive.

User Image Draven666 Posted - 1 hour ago

$ME there's beauty in the simplicity of the failure.

User Image wilosmiles Posted - 10 hours ago

$ME geeez not another big red candle

User Image Draven666 Posted - 16 hours ago

$ME it's nice to see satire still exists.

User Image lzwa Posted - 18 hours ago

$ME sad

User Image HushNLearn Posted - 19 hours ago

$ME damn

User Image NumberWang Posted - 20 hours ago

$ME $SPCE You can lead a horse to the river, but you cannot make it drink.

User Image Nay_Nay Posted - 22 hours ago

$ME Just delist and get it over with already. Everyone that owns this is underwater anyways. Another write off against future gains in the profolios Fucking clown show

User Image wilosmiles Posted - 1 day ago

$ME crappy stock

User Image Draven666 Posted - 4 days ago

$ME gonna be delisted cuz Anne won't:

User Image Coins8 Posted - 4 days ago

$ME boom or bust here soon! Fingers crossed

User Image wilosmiles Posted - 5 days ago

$ME what a mismanaged company... useful service no doubt helping society. great service, terrible stock.

User Image trade_a_lot Posted - 5 days ago

@lordwilmore @crazymoney123 @Draven666 I am hoping that they are working on something. Best options that I can think of: 1. Merge consumer with Ancestry via $BX . Tons of synergies there. Worlds largest DNA database. 2 best brands. Cross sell/ upsell ancestry and health. 2. SPAC out the therapeutics division to get rid of burn and get some cash. Shareholders get shares in new SPAC co 3. JV or sell therapeutics division with $GSK. GSK covers all costs and keeps majority of revenues and pays royalty to $ME along with upfront payment. Exclusivity deal. 4. Options 1 and 3 together at the same time Any of these will send stock over $1.

User Image Coins8 Posted - 5 days ago

$ME partnership, insurance coverage, company division or positive news on clinic will make this baby soar the backing is there just needs volume and sentiment

User Image lordwilmore Posted - 5 days ago

$ME good article to read. Keep eye out for potential entity split: therapeutics v consumer. Covered by FT Not financial advice or concrete plans. This is all speculation https://www.ft.com/content/b6b5c33f-1eb5-446e-9024-bd11d12a9cb0

User Image HushNLearn Posted - 5 days ago

$ME This one has $ME going like this

User Image Educated_Degenerate Posted - 6 days ago

$ME had to add sub $0.46, I know I’m the one one.

User Image Educated_Degenerate Posted - 6 days ago

$ME plenty of volume to the short side, now at 32,500,000 shares short. Unbelievable

User Image crazymoney123 Posted - 6 days ago

$ME how many days left to get it over a dollar? And it has to be ten consecutive before deadline right.

User Image BottomFishingCharts Posted - 6 days ago

$ME is starting to warm up to the idea of popping that 21 day EMA and sticking it. #LetsGo...

User Image HoodrichInvestor Posted - 1 week ago

$ME Dead volume....dead stock.

User Image Coins8 Posted - 1 week ago

$ME https://www.defenseworld.net/2024/04/08/china-universal-asset-management-co-ltd-increases-holdings-in-23andme-holding-co-nasdaqme.html

User Image HushNLearn Posted - 1 week ago

$ME Discount or something else?

User Image petrofornow Posted - 1 week ago

$ME the new 23andMe cancer therapy slides are now on the investor website. the results look very promising. they combine the 23andMe therapy with pd1 antibody and the result appears to be successful tumor reduction. trials should follow. why big pharma has not bought 23andMe given current share price is very strange. imagine how many therapies they could develop given their larger scale and resources

User Image BottomFishingCharts Posted - 1 week ago

$ME.. Higher low/high with a momentum pivot.. #LetsGo.. Get you butt back into the channel...

User Image swefo Posted - 1 week ago

$ME

User Image Draven666 Posted - 1 week ago

$ME prior news they brought forth like this resulted in a very short term uptick which quickly reversed.

User Image Deadman3906 Posted - 1 week ago

$PLUG $ME $GOOD

Analyst Ratings
Citigroup Buy Aug 10, 23
Credit Suisse Outperform May 26, 23
Citigroup Neutral May 26, 23
Berenberg Buy Nov 29, 22
Credit Suisse Outperform Nov 8, 22
Cowen & Co. Outperform Sep 22, 22
Citigroup Neutral Aug 10, 22
Credit Suisse Outperform May 27, 22
Citigroup Neutral May 27, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 25 Sell 0.73 38,548 28,140 1,280,349 01/26/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 25 Option 0.42 38,548 16,190 1,318,897 01/26/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 11 Sell 0.72 38,548 27,755 1,280,349 01/12/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jan 11 Option 0.42 38,548 16,190 1,318,897 01/12/24
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Nov 02 Sell 0.87 38,548 33,537 1,284,976 11/03/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Nov 02 Option 0.42 38,548 16,190 1,323,524 11/03/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 19 Sell 0.81 38,548 31,224 1,284,976 10/20/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 19 Option 0.42 38,548 16,190 1,323,524 10/20/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 05 Option 0.42 38,548 16,190 1,323,524 10/06/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Oct 05 Sell 0.84 38,548 32,380 1,284,976 10/06/23
Richards William G Head of Therapeutics.. Head of Therapeutics Discovery Sep 05 Sell 1.08 2,538 2,741 211,041 09/06/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Aug 15 Sell 1.32 40,894 53,980 257,140 08/16/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Aug 15 Option 0.42 40,894 17,175 298,034 08/16/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jun 29 Sell 1.72 40,894 70,338 257,140 06/30/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Jun 29 Option 0.42 40,894 17,175 298,034 06/30/23
HIBBS KATHY L Chief Administrative.. Chief Administrative Officer Dec 05 Sell 3.25 26,259 85,342 235,829 12/06/22
Hillan Kenneth J. Chief Therapeutics O.. Chief Therapeutics Officer Aug 24 Sell 3.64 8,753 31,861 196,083 08/25/22
Lovell Evan Director Director Mar 10 Buy 4.409 11,467 50,558 11,467 03/11/22